The present invention belongs to a new and advantageous dosage regime for a humanized PEGylated monovalent anti-CD28 Fab 'antibody fragment called "FR104". This dosage regimen is once a week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, once every eight weeks, or more than eight weeks. Consists of FR104, which is between 0.05 and 1.5 mg / kg body weight on a single dosing schedule.本発明は、「ＦＲ１０４」と呼ばれる、ヒト化ペグ化一価抗ＣＤ２８Ｆａｂ’抗体断片の為の新規で並びに有利な投薬管理に属する。この投薬管理は、週に一度、２週間に一度、３週間に一度、４週間に一度、５週間に一度、若しくは６週間に一度、７週間に一度、８週間に一度、又は８週間以上に一度の投薬計画で、０．０５～１．５ｍｇ／ｋｇ体重の間である、ＦＲ１０４で構成される。
